UNASSIGNED:为了确定早期反应评估是否可以预测抗血管内皮生长因子(VEGF)治疗视网膜静脉阻塞(RVO-ME)继发黄斑水肿的长期疗效。
UNASSIGNED:对诊断为RVO-ME和玻璃体内抗VEGF治疗的患者进行回顾性研究。临床特征包括年龄,性别,基线时记录疾病亚型和病程.最佳矫正视力(BCVA和logMAR),眼内压(IOP),和中央黄斑厚度(CMT)记录在基线,2周,和注射后的每个月(1-6个月)。Further,我们比较了治愈组(6个月CMT≤250μm)和未治愈组(6个月CMT>250μm)的早期反应评估.
UNASSIGNED:共164眼(男性77例,女性87例)。在每个注射后时间点,BCVA和CMT均较基线显著降低(均P<0.001).Spearman检验显示,首次注射后2周CMT降低率与6个月时BCVA呈负相关(r=-0.359,P<0.001)。与未治愈组(47例)相比,治愈组(117例)年轻(59.53±11.68vs.65.19±13.10岁,P<0.01),有更多的BRVO患者(76.1%vs.44.7%,P<0.01),疾病持续时间较短(1.92±2.43vs.5.05±4.32个月,P<0.01),较低基线CMT(527.09±154.95vs.768.96±287.75μm,P<0.01),和较低的基线BCVA(0.86±0.44vs.1.31±0.51,P<0.01)。在每个注射后时间点,与未治愈组相比,治愈组的CMT和BCVA值均较低(均P<0.01),2周CMT降低率被确定为预测长期治疗疗效的最早缓解时间。此外,ROC曲线分析表明,2周CMT降低率>37%是预测抗VEGF治疗6个月长期治愈的最佳临界点(P<0.001)。多因素logistic回归分析证实2周CMT降低率>37%与6个月治愈率独立相关(OR=9.639,95%Cl=1.030~90.227,P=0.047)。
未经批准:年龄,疾病持续时间,基线CMT,和基线BCVA与RVO-ME抗VEGF治疗6个月时的视力结果相关。首次注射后的“2周CMT降低率>37%”是预测更好的长期结果的独立因素。
UNASSIGNED: To determine if the early response assessments can predict the long-term efficacy of anti-vascular endothelial growth factor (VEGF) treatment for macular edema secondary to retinal vein occlusion (RVO-ME).
UNASSIGNED: A retrospective study of patients with diagnosis of RVO-ME and intravitreal anti-VEGF treatment was conducted. Clinical characteristics including age, gender, disease subtype and disease duration were recorded at baseline. The best corrected visual acuity (BCVA and logMAR), intraocular pressure (IOP), and central macular thickness (CMT) were recorded at baseline, 2 weeks, and every month (months 1-6) after injection. Further, we compared the early response assessments between the cured group (6-month CMT ≤ 250 μm) and the uncured group (6-month CMT > 250 μm).
UNASSIGNED: A total of 164 eyes in 164 patients (77 male and 87 female) were included. At each post-injection time point, both BCVA and CMT are significantly decreased from baseline (all P < 0.001). Spearman\'s test showed that 2-week CMT reduction rate after the first injection was negatively correlated with BCVA at 6 months (r = -0.359, P < 0.001). Compared with the uncured group (47 cases), the cured group (117 cases) was younger (59.53 ± 11.68 vs. 65.19 ± 13.10 years old, P < 0.01), had more BRVO patients (76.1% vs. 44.7%, P < 0.01), a shorter disease duration (1.92 ± 2.43 vs. 5.05 ± 4.32 months, P < 0.01), lower baseline CMT (527.09 ± 154.95 vs. 768.96 ± 287.75 μm, P < 0.01), and lower baseline BCVA (0.86 ± 0.44 vs. 1.31 ± 0.51, P < 0.01). At each post-injection time point, the cured group had lower CMT and BCVA values when compared to the uncured group (all P < 0.01), and the 2-week CMT reduction rate was identified as the earliest response time to predict the long-term treatment efficacy. Moreover, ROC curve analysis indicated that a 2-week CMT reduction rate >37% yielded the best cut-off point for predicting the long-term cure of anti-VEGF treatment at 6 months (P < 0.001). Multivariable logistic regression confirmed that the 2-week CMT reduction rate >37% was independently associated with the 6-month cured rate (OR = 9.639, 95% Cl = 1.030-90.227, P = 0.047).
UNASSIGNED: Age, disease duration, baseline CMT, and baseline BCVA are associated with visual outcomes at 6-month of anti-VEGF treatment for RVO-ME. The \"2-week CMT reduction rate >37%\" after the first injection is an independent factor to predict better long-term outcomes.